{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:41:26Z","timestamp":1790988086668,"version":"4.1.0"},"reference-count":12,"publisher":"American Society for Microbiology","issue":"1","license":[{"start":{"date-parts":[[2009,1,1]],"date-time":"2009-01-01T00:00:00Z","timestamp":1230768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>Rifaximin, ampicillin-sulbactam, neomycin, nitazoxanide, teicoplanin, and vancomycin were tested against 536 strains of anaerobic bacteria. The overall MIC of rifaximin at which 50% of strains were inhibited was 0.25 \u03bcg\/ml. Ninety percent of the strains tested were inhibited by 256 \u03bcg\/ml of rifaximin or less, an activity equivalent to those of teicoplanin and vancomycin but less than those of nitazoxanide and ampicillin-sulbactam.<\/jats:p>","DOI":"10.1128\/aac.00441-08","type":"journal-article","created":{"date-parts":[[2008,10,28]],"date-time":"2008-10-28T00:26:04Z","timestamp":1225153564000},"page":"281-286","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":38,"title":["Study of the In Vitro Activities of Rifaximin and Comparator Agents against 536 Anaerobic Intestinal Bacteria from the Perspective of Potential Utility in Pathology Involving Bowel Flora"],"prefix":"10.1128","volume":"53","author":[{"given":"S. M.","family":"Finegold","sequence":"first","affiliation":[{"name":"Medical"},{"name":"Research Services, VA Greater Los Angeles Healthcare System"},{"name":"Departments of Medicine"},{"name":"Microbiology, Immunology, and Molecular Genetics, UCLA School of Medicine, Los Angeles, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Molitoris","sequence":"additional","affiliation":[{"name":"Research Services, VA Greater Los Angeles Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-L.","family":"Va\u0308isa\u0308nen","sequence":"additional","affiliation":[{"name":"Research Services, VA Greater Los Angeles Healthcare System"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1086\/499950"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1179\/joc.2002.14.3.290"},{"key":"e_1_3_2_4_2","first-page":"51","volume":"14","year":"1994","unstructured":"Descombe, J. J., D. Dubourg, M. Picard, and E. Palazzini. 1994. Pharmacokinetic study of rifaximin after oral administration in healthy volunteers. Int. J. Clin. Pharmacol. Res.14:51-56.","journal-title":"Int. J. Clin. Pharmacol. Res."},{"key":"e_1_3_2_5_2","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jinf.2004.05.019","volume":"50","year":"2005","unstructured":"Huang, D., and H. DuPont. 2005. Rifaximin\u2014a novel antimicrobial for enteric infections. J. Infect.50:97-106.","journal-title":"J. Infect."},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.8.2205-2206.2000"},{"key":"e_1_3_2_7_2","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","volume":"44","year":"2007","unstructured":"Johnson, S., C. Schriever, M. Galang, C. P. Kelly, and D. N. Gerding. 2007. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin. Infect. Dis.44:846-848.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_2_8_2","unstructured":"Wadsworth-KTL anaerobic bacteriology manual 2002"},{"key":"e_1_3_2_9_2","unstructured":"Methods for antimicrobial susceptibility testing of anaerobic bacteria: approved standard 2004"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00342-08"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.4.1363-1369.2003"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.36.8.1658"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01108-07"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00441-08","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.00441-08","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T19:45:13Z","timestamp":1645472713000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.00441-08"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1128\/AAC.00441-08"],"URL":"https:\/\/doi.org\/10.1128\/aac.00441-08","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,1]]},"assertion":[{"value":"2008-04-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2008-10-17","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2009-01-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}